Eribulin Injection 0.88 mg is an anti-cancer agent which works by stopping the growth and spread of cancer cells.
It is used for locally advanced or metastatic breast cancer (breast cancer that has spread beyond the original tumour) when at least one other therapy has been tried but has lost its effect.
India has many manufacturers who manufacture Eribulin Injection 0.88 mg .To know more contact us.
3s corporation is supplier,Exporter ,Wholesaler for Eribulin Injection 0.88 mg in India.
Eribulin Injection 0.88 mg will be given to patient by a doctor or nurse as an injection into a vein, over a period of 2 to 5 minutes. The dose that patient will receive is based on patient body surface area (expressed in squared metres, or m2) which is calculated from patient’s weight and height. The usual dose of Eribulin Injection 0.88 mg is 1.23 mg/m2, but this may be adjusted by doctor based on patient’s blood test results or other factors.
Very common side effects (reported in at least 1 out of 10 patients) are:
Decrease in the number of white blood cells or red blood cells
Tiredness or weakness
Nausea, vomiting, constipation, diarrhoea
Numbness, tingling or prickling sensations
Loss of appetite, weight loss
Difficulty breathing, cough
Pain in the joints and muscles and back
Common side effects (reported in at least 1 out of 100 patients) are:
Decrease in the number of platelets (which may result in bruising or taking longer to stop bleeding)
Infection with fever, pneumonia, chills
Fast heart rate, flushing
Increased production of tears, conjunctivitis (redness and soreness of the surface of the eye), nosebleed